Press Release
Sett Emerges From Stealth With $27 Million to Bring AI at Scale to Mobile Games Studios
Sett's agentic AI platform creates high-performing marketing and in-game content automatically, at scale, and based on real campaign data. It helps mobile gaming studios move faster, cut production time, and stay competitive in the $100 billion gaming market. Read More
Press Release
Interactive Strength Inc. (Nasdaq:TRNR) Provides Shareholder Update on Sportstech’s Strong April 2025 and LTM Performance
Sportstech Announced Strong Results, with April 2025 revenue growth at 36% YOY Current FX rates indicate that the LTM figures would be approximately $54M in Revenue and $5M in EBITDA through April 2025 Strong Business Momentum, Revenue and Positive EBITDA Underscore Target's Operational Strength and Logic of Acquisition in advance of Closing Read More
Press Release
DEA Marijuana SCAM Violates the Public Interest, MMJ To File Suit Against DEA Yet Again
DEA's Diversion Control Division leadership implicated in the obstruction of MMJ 's DEA registration and delays in cannabis-based pharmaceutical research are Thomas W. Prevoznik, Matthew Strait and DEA Administrative Law Judges (ALJs) all who under the agency's control, raising serious concerns about due process, impartiality, and accountability. Read More
Press Release
BrainGu Promotes Jamil Jadallah to Vice President of Product, Advancing Vision for a Product-Led Future
Jamil's experience building scalable platforms, combined with his clear focus on the developer journey, makes him the perfect leader to advance our vision for a product-led future and to drive the next era of growth. Read More
Press Release
FINRA Arbitrators Find Major Brokerage Liable to Investors for Punitive Damages in Cherry-Picking Fraud Scheme Run by Outside Advisor
First-of-Its-Kind Ruling Holds Charles Schwab & Co., Inc. Liable to Investors for Facilitating and Concealing RIA Fraud; Skipp Cook and Raymond McCleary vs. TD Ameritrade, Inc., TD Ameritrade Clearing, Inc., and Charles Schwab & Co., Inc., FINRA Arbitration Case No. 23-03586 Read More
Press Release
Battery X Metals Achieves Procedural Milestone with Global Top 20 University, Reporting Increases in Graphite Purity and Oxide Recovery Ahead of Additional Controlled Trials
News Release Highlights: Identification of a new solvent that enhances separation of oxides from graphite in Battery X Recycling Technologies' proprietary eco-friendly flotation process. Preliminary trial results show a 26.5% to 31.5% relative increase in oxide recovery (from 36.59% to 38.03 in prior tests to 48.10%) and a 5.5% to 6.3% relative increase in graphite purity (from 68.66% to 69.20% in prior tests to 73.0%). Graphite recovery remained high at ~97% (96.30%), oxide purity remained consistent at ~90% (89.90%), and flotation time held steady at 5-7 minutes; further trials underway to optimize solvent use and flotation stages. Read More
Press Release
eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health
N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity. eXoZymes used its AI-driven development platform to progress from idea to purpose-built subsidiary in less than 3 months and at a fraction of normal SynBio R&D cost. NCTx is scaling up an exozyme biosolution to overcome a longstanding bottleneck in sourcing the NCT compound from nature, where it occurs only in trace amounts. Interesting pre-clinical data point towards Non-Alcoholic Fatty Liver Disease (NAFLD) that affects more than 30% of the global population. Only NCTx can make both the natural product NCT, and a range of very interesting new-to-nature analog versions, expanding the pharma potential. NCT is the first of more "powered by eXoZymes" natural product nutraceuticals, that also have the potential to become pharmaceuticals. Read More
Press Release
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCO Full dataset from Phase 3 ICONIC-LEAD trial with icotrokinra in patients with moderate-to-severe plaque psoriasis (PsO) presented at the 2025 AAD Meeting in March; data from adolescent subset presented at World Congress of Pediatric Dermatology in April Positive top line results from icotrokinra Phase 2b ANTHEM trial in moderately to severely active ulcerative colitis (UC) announced in March, data to be presented at medical conference later in 2025 Cash, cash equivalents and marketable securities of $697.9 million as of March 31, 2025, anticipated to provide cash runway through at least end of 2028 Read More
Press Release
Electronic Caregiver Launches First-Ever AI-Powered Virtual Care Ecosystem Featuring Interactive Avatar, Now Available via Athenahealth’s EHR Network
Addison Care delivers the industry's most comprehensive AI-enabled chronic care platform - offering vitals monitoring, automated wellness checks, caregiver support, and integrated TeleCare services - now accessible to thousands of clinics through Athenahealth's nationwide EHR ecosystem. Read More
Press Release
